Drug repurposing of triazoles against mucormycosis using molecular docking: A short communication.
Comput Biol Med
; 136: 104722, 2021 09.
Article
in English
| MEDLINE | ID: covidwho-1330723
ABSTRACT
BACKGROUND:
Mucormycosis, a fungal infection caused by Rhizopus species is on the rise in COVID-19 patients as a result of their suppressed immunity. The current therapies include systemic administration of Amphotericin B. HYPOTHESIS ANDMETHOD:
We screened several triazole broad-spectrum antifungal agents against the therapeutic target in mucormycosis using computational techniques like molecular docking and compared them with isavuconazole, an approved drug.RESULT:
The study concluded that 4 triazole drugs, pramiconazole, itraconazole, posaconazole and ketoconazole were strong candidates to be further evaluated and developed as a treatment for mucormycosis.CONCLUSION:
Novel topical and oral therapies could be developed from these drug leads.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Mucormycosis
Type of study:
Experimental Studies
Limits:
Humans
Language:
English
Journal:
Comput Biol Med
Year:
2021
Document Type:
Article
Affiliation country:
J.compbiomed.2021.104722
Similar
MEDLINE
...
LILACS
LIS